{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:58:08Z","timestamp":1794549488894,"version":"4.9.1"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0570-8","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T06:13:33Z","timestamp":1554963213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation"],"prefix":"10.1136","volume":"7","author":[{"given":"Anne M\u00e5nsson","family":"Kvarnhammar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Veitonm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"H\u00e4gerbrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dahlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Enell","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fritzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"von Schantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Thagesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Werchau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Smedenfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ros\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"\u00c5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Winnerstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Nyblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Barchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Furebring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Norl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ellmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"issue":"1","key":"570_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","volume":"29","author":"J Tang","year":"2018","unstructured":"Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84\u201391.","journal-title":"Ann Oncol"},{"issue":"9","key":"570_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386.","journal-title":"Cancer Discov"},{"issue":"1","key":"570_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"570_CR4","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.molonc.2015.10.008","volume":"9","author":"A Sledzinska","year":"2015","unstructured":"Sledzinska A, Menger L, Bergerhoff K, Peggs KS, Quezada SA. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol. 2015;9(10):1936\u201365.","journal-title":"Mol Oncol"},{"issue":"3","key":"570_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2249.2004.02478.x","volume":"136","author":"CB Jago","year":"2004","unstructured":"Jago CB, Yates J, Camara NO, Lechler RI, Lombardi G. Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol. 2004;136(3):463\u201371.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"570_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","volume":"33","author":"F Arce Vargas","year":"2018","unstructured":"Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. 2018;33(4):649\u201363.","journal-title":"Cancer Cell"},{"issue":"4","key":"570_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.16","volume":"5","author":"R Montler","year":"2016","unstructured":"Montler R, Bell RB, Thalhofer C, Leidner R, Feng Z, Fox BA, et al. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin Transl Immunology. 2016;5(4):e70.","journal-title":"Clin Transl Immunology"},{"issue":"4","key":"570_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41422-018-0011-0","volume":"28","author":"X Du","year":"2018","unstructured":"Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res. 2018;28(4):416\u201332.","journal-title":"Cell Res"},{"issue":"4","key":"570_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191926","volume":"13","author":"RB Gombos","year":"2018","unstructured":"Gombos RB, Gonzalez A, Manrique M, Chand D, Savitsky D, Morin B, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018;13(4):e0191926.","journal-title":"PLoS One"},{"issue":"15","key":"570_CR10","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1073\/pnas.1801524115","volume":"115","author":"JR Ingram","year":"2018","unstructured":"Ingram JR, Blomberg OS, Rashidian M, Ali L, Garforth S, Fedorov E, et al. Anti-CTLA-4 therapy requires an fc domain for efficacy. Proc Natl Acad Sci U S A. 2018;115(15):3912\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"570_CR11","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci. 2015;112(19):6140\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"570_CR12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"Anu Sharma","year":"2018","unstructured":"Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo JA, et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clin Cancer Res. 2018. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0762\n                    \n                  .","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"570_CR13","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1158\/1078-0432.CCR-18-2509","volume":"25","author":"Sergio A. Quezada","year":"2018","unstructured":"Quezada SA, Peggs KS. Lost in Translation: Deciphering the mechanism of action of anti-human CTLA-4. Clin Cancer Res. 2018. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2509\n                    \n                  .","journal-title":"Clinical Cancer Research"},{"issue":"17","key":"570_CR14","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889\u201394.","journal-title":"J Clin Oncol"},{"issue":"17","key":"570_CR15","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.ejca.2015.08.012","volume":"51","author":"Z Eroglu","year":"2015","unstructured":"Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, et al. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015;51(17):2689\u201397.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"570_CR16","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1111\/j.1743-7563.2010.01271.x","volume":"6","author":"FS Hodi","year":"2010","unstructured":"Hodi FS. Overcoming immunological tolerance to melanoma: Targeting CTLA-4. Asia Pac J Clin Oncol. 2010;6(Suppl 1):S16\u201323.","journal-title":"Asia Pac J Clin Oncol"},{"key":"570_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.","journal-title":"BMC Med"},{"issue":"1","key":"570_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-016-1909-3","volume":"66","author":"P Ellmark","year":"2017","unstructured":"Ellmark P, Mangsbo SM, Furebring C, Norlen P, Totterman TH. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunol Immunother. 2017;66(1):1\u20137.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"570_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0002-9610(97)00139-6","volume":"174","author":"JT Vetto","year":"1997","unstructured":"Vetto JT, Lum S, Morris A, Sicotte M, Davis J, Lemon M, et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg. 1997;174(3):258\u201365.","journal-title":"Am J Surg"},{"key":"570_CR20","doi-asserted-by":"crossref","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019.","DOI":"10.1038\/s41573-018-0007-y"},{"issue":"2","key":"570_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2326-6066.CIR-13-0031-T","volume":"2","author":"WL Redmond","year":"2014","unstructured":"Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res. 2014;2(2):142\u201353.","journal-title":"Cancer Immunol Res."},{"issue":"3","key":"570_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40259-018-0277-2","volume":"32","author":"DA Emerson","year":"2018","unstructured":"Emerson DA, Redmond WL. Overcoming tumor-induced immune suppression: from relieving inhibition to providing Costimulation with T cell agonists. BioDrugs. 2018;32(3):221\u201331.","journal-title":"BioDrugs."},{"issue":"7","key":"570_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrd.2018.75","volume":"17","author":"PA Mayes","year":"2018","unstructured":"Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018;17(7):509\u201327.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"570_CR24","first-page":"359","volume":"27","author":"BS Glisson","year":"2016","unstructured":"Glisson BS, Leidner R, Ferris RL, Powderly J, Rizvi N, Norton JD, Burton J, Lanasa MC, Patel SP. Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors. Ann Oncol. 2016;27(6):359\u201378.","journal-title":"Ann Oncol"},{"issue":"10","key":"570_CR25","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/bjc.2013.645","volume":"109","author":"HB Jie","year":"2013","unstructured":"Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013;109(10):2629\u201335.","journal-title":"Br J Cancer"},{"key":"570_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3389\/fimmu.2017.00619","volume":"8","author":"AS Syed Khaja","year":"2017","unstructured":"Syed Khaja AS, Toor SM, El Salhat H, Ali BR, Elkord E. Intratumoral FoxP3(+)Helios(+) regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal Cancer. Front Immunol. 2017;8:619.","journal-title":"Front Immunol"},{"issue":"1","key":"570_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40425-014-0029-x","volume":"2","author":"R Stewart","year":"2014","unstructured":"Stewart R, Hammond SA, Oberst M, Wilkinson RW. The role of fc gamma receptors in the activity of immunomodulatory antibodies for cancer. Journal for ImmunoTherapy of Cancer. 2014;2(1):29.","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"570_CR28","doi-asserted-by":"crossref","unstructured":"Waight JD, Gombos RB, Wilson NS. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: current approaches and future opportunities. Hum Antibodies. 2017.","DOI":"10.3233\/HAB-160308"},{"issue":"6","key":"570_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ccell.2018.05.005","volume":"33","author":"JD Waight","year":"2018","unstructured":"Waight JD, Chand D, Dietrich S, Gombos R, Horn T, Gonzalez AM, et al. Selective FcgammaR co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens. Cancer Cell. 2018;33(6):1033\u201347 e5.","journal-title":"Cancer Cell"},{"key":"570_CR30","unstructured":"Stone E, O'Brien EM, Sanseviero E, Karras J, Shabaneh T, Aksoy BA, et al., Editors. Anti-CTLA4 activation of intratumoral NK cells may contribute to intratumoral Treg depletion. SITC'18, Washington DC; 9-11 November 2018. 6(suppl 1), Abstract O40."},{"issue":"1","key":"570_CR31","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27614","volume":"3","author":"LC Sandin","year":"2014","unstructured":"Sandin LC, Eriksson F, Ellmark P, Loskog AS, Totterman TH, Mangsbo SM. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology. 2014;3(1):e27614.","journal-title":"Oncoimmunology."},{"issue":"1","key":"570_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","volume":"1","author":"M. J. Selby","year":"2013","unstructured":"Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1.","journal-title":"Cancer Immunology Research"},{"issue":"9","key":"570_CR33","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695\u2013710.","journal-title":"J Exp Med"},{"issue":"3","key":"570_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/CJI.0b013e3181c01fcb","volume":"33","author":"SM Mangsbo","year":"2010","unstructured":"Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 2010;33(3):225\u201335.","journal-title":"J Immunother"},{"issue":"7","key":"570_CR35","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1172\/JCI27745","volume":"116","author":"SA Quezada","year":"2006","unstructured":"Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006;116(7):1935\u201345.","journal-title":"J Clin Invest"},{"issue":"8","key":"570_CR36","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1073\/pnas.0712237105","volume":"105","author":"FS Hodi","year":"2008","unstructured":"Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105(8):3005\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"51","key":"570_CR37","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"570_CR38","doi-asserted-by":"publisher","first-page":"14987","DOI":"10.1073\/pnas.0806075105","volume":"105","author":"CI Liakou","year":"2008","unstructured":"Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008;105(39):14987\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"570_CR39","doi-asserted-by":"crossref","unstructured":"Ferrara R, Susini S, Marabelle A. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers-letter. Clin Cancer Res. 2018.","DOI":"10.1158\/1078-0432.CCR-18-3740"},{"issue":"1","key":"570_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/0300985811429314","volume":"49","author":"RS Sellers","year":"2012","unstructured":"Sellers RS, Clifford CB, Treuting PM, Brayton C. Immunological variation between inbred laboratory mouse strains: points to consider in phenotyping genetically immunomodified mice. Vet Pathol. 2012;49(1):32\u201343.","journal-title":"Vet Pathol"},{"issue":"2","key":"570_CR41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3892\/ijo.2016.3561","volume":"49","author":"A Fiserova","year":"2016","unstructured":"Fiserova A, Richter J, Capkova K, Bieblova J, Mikyskova R, Reinis M, et al. Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors. Int J Oncol. 2016;49(2):763\u201372.","journal-title":"Int J Oncol"},{"issue":"3","key":"570_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"A Elsas van","year":"1999","unstructured":"van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190(3):355\u201366.","journal-title":"J Exp Med"},{"issue":"4","key":"570_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ijc.11696","volume":"109","author":"D Xu","year":"2004","unstructured":"Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer. 2004;109(4):499\u2013506.","journal-title":"Int J Cancer"},{"issue":"9","key":"570_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161779","volume":"11","author":"MJ Selby","year":"2016","unstructured":"Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, Thudium K, et al. Preclinical development of Ipilimumab and Nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and Cynomolgus macaque toxicology. PLoS One. 2016;11(9):e0161779.","journal-title":"PLoS One"},{"key":"570_CR45","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017.","DOI":"10.1056\/NEJMoa1709684"},{"issue":"8","key":"570_CR46","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722\u201330.","journal-title":"N Engl J Med"},{"issue":"21","key":"570_CR47","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006\u201317.","journal-title":"N Engl J Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0570-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:44:07Z","timestamp":1601055847000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0570-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0570-8","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"27 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee in Malm\u00f6\/Lund, Sweden (approval number M142\u201315) and was conducted in accordance with International ethics guidelines, including the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have been or are employees of Alligator Bioscience AB and have stocks and\/or stock options in Alligator Bioscience AB. The authors do not have any financial competing interests. All the company-employed authors declare that their employment does not alter their adherence to the policies of Journal for Immunotherapy of Cancer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"103"}}